isavuconazole and Primary-Myelofibrosis

Invasive aspergillosis (IA) is the most common invasive fungal infection following a hematopoietic cell transplant, with emerging cryptic species exhibiting resistance to commonly used antifungals such as azoles. These species have been increasingly found after the introduction of anti-mold prophylaxis. We report a case of a 56-year-old female with primary myelofibrosis whose allogeneic hematopoietic cell transplant was complicated by disseminated fungal infection (skin, lung) due to Aspergillus calidoustus, a cryptic specie. Treatment of Aspergillus species remains challenging as these cryptic species are usually resistant to azoles including voriconazole which is the first line of treatment of IA. Infection was successfully treated with surgical excision and combination antifungal therapy based on in vitro susceptibility and synergy testing. Therapy included isavuconazole, a drug that has been shown to be non-inferior to voriconazole in the treatment of invasive mold infections.

Topics: Antifungal Agents; Aspergillosis; Aspergillus; Azoles; Drug Resistance, Fungal; Female; Hematopoietic Stem Cell Transplantation; Humans; Invasive Fungal Infections; Microbial Sensitivity Tests; Middle Aged; Nitriles; Primary Myelofibrosis; Pyridines; Triazoles